PulseAugur
EN
LIVE 14:33:53
中文(ZH) 在代谢酶网络里，默达生物找到了一个让坏细胞「吃不饱饭」的开关

Mura Bio targets immune cell metabolism for autoimmune disease treatments

By PulseAugur Editorial · [1 sources] ·

Mura Bio, a startup co-founded by Dr. Xu Ke, is developing novel treatments for autoimmune diseases by targeting the metabolic pathways of immune cells. Their lead candidate, MP-5342, is an oral LDHA inhibitor designed to starve "bad" immune cells, offering a potentially safer alternative to existing immunosuppressants with a significantly wider safety window. The company is also developing META-001-PH for primary hyperoxaluria, a rare genetic metabolic disorder. Mura Bio leverages AI for drug discovery, focusing on rapid screening of potential drug candidates and analyzing multi-omics data from patients to identify therapeutic targets. AI

IMPACT Mura Bio's approach highlights AI's role in accelerating drug discovery by enabling rapid screening and patient data analysis for novel therapeutic targets.

RANK_REASON Startup Mura Bio developing novel drug candidates for autoimmune diseases and rare metabolic disorders, leveraging AI in drug discovery. [lever_c_demoted from significant: ic=1 ai=0.7]

Read on 雷峰网 (Leiphone) →

AI-generated summary · Google Gemini · from 1 sources. How we write summaries →

Mura Bio targets immune cell metabolism for autoimmune disease treatments

How we ranked this

Signal score
10 / 100
Composite score across the factors below. Higher = stronger signal that this story matters right now.
Newsworthiness bucket
Research
Startup Mura Bio developing novel drug candidates for autoimmune diseases and rare metabolic disorders, leveraging AI in drug discovery. [lever_c_demoted from significant: ic=1 ai=0.7]
Source corroboration
Single-source cluster
Only one publisher covered this so far. Single-source stories can still rank when the publisher is high-authority, but they lack cross-source corroboration.
Topics
model release, product, other
Editorial topic classification. Feeds into how the story surfaces on /topic/<slug> hub pages and into the per-entity coverage mix.
AI-industry relevance
High
Clearly on-topic for AI-industry coverage.
Story freshness
Breaking (< 6h)
Fresh story with cross-source coverage still developing. Ranking may shift as more sources report.

Full methodology in our editorial standards.

COVERAGE [1]

  1. 雷峰网 (Leiphone) TIER_1 中文(ZH) ·

    In the metabolic enzyme network, Mura Bio found a switch that makes bad cells "starve"

    <section style="text-align: center; margin: 0px 16px; line-height: 1.75em; display: block;"><img class="rich_pages wxw-img" src="https://static.leiphone.com/uploads/new/images/20261030/6ae468170826e.jpg?imageMogr2/quality/90" style="width: 100%; display: inline-block; text-align:…

RELATED ENTITIES

RELATED TOPICS